Logan Capital Management Inc. Sells 38,448 Shares of Pfizer Inc. (NYSE:PFE)

Logan Capital Management Inc. decreased its position in Pfizer Inc. (NYSE:PFE) by 7.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 450,009 shares of the biopharmaceutical company’s stock after selling 38,448 shares during the period. Logan Capital Management Inc.’s holdings in Pfizer were worth $12,956,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of PFE. GoalVest Advisory LLC grew its position in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares in the last quarter. VisionPoint Advisory Group LLC grew its position in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the period. Tennessee Valley Asset Management Partners bought a new position in shares of Pfizer during the 4th quarter valued at approximately $36,000. DiNuzzo Private Wealth Inc. bought a new position in shares of Pfizer during the 4th quarter valued at approximately $37,000. Finally, Life Planning Partners Inc bought a new position in shares of Pfizer during the 4th quarter valued at approximately $39,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 0.8 %

NYSE PFE traded down $0.22 on Friday, hitting $28.58. The stock had a trading volume of 27,526,200 shares, compared to its average volume of 33,056,490. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The stock has a market cap of $161.95 billion, a price-to-earnings ratio of -476.25, a price-to-earnings-growth ratio of 1.12 and a beta of 0.70. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.37. The business’s fifty day moving average price is $27.50 and its 200 day moving average price is $27.86.

Pfizer (NYSE:PFE) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The company had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm’s quarterly revenue was down 19.5% on a year-over-year basis. During the same quarter last year, the business posted $1.23 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.88%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Analysts Set New Price Targets

PFE has been the topic of several research reports. Morgan Stanley increased their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Ten investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $35.86.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.